470 related articles for article (PubMed ID: 33309857)
1. Galactosyltransferase B4GALT1 confers chemoresistance in pancreatic ductal adenocarcinomas by upregulating N-linked glycosylation of CDK11
Chen Y; Su L; Huang C; Wu S; Qiu X; Zhao X; Meng Q; Meng YM; Kong X; Wang M; Liu C; Wong PP
Cancer Lett; 2021 Mar; 500():228-243. PubMed ID: 33309857
[TBL] [Abstract][Full Text] [Related]
2. LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma.
Okada Y; Takahashi N; Takayama T; Goel A
Carcinogenesis; 2021 Apr; 42(4):546-556. PubMed ID: 33624791
[TBL] [Abstract][Full Text] [Related]
3. Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Zhang D; Li L; Jiang H; Knolhoff BL; Lockhart AC; Wang-Gillam A; DeNardo DG; Ruzinova MB; Lim KH
Clin Cancer Res; 2017 Apr; 23(7):1748-1759. PubMed ID: 27702822
[No Abstract] [Full Text] [Related]
4. Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Gifford JB; Huang W; Zeleniak AE; Hindoyan A; Wu H; Donahue TR; Hill R
Mol Cancer Ther; 2016 May; 15(5):1043-52. PubMed ID: 26939701
[TBL] [Abstract][Full Text] [Related]
5. PTBP3 promotes malignancy and hypoxia-induced chemoresistance in pancreatic cancer cells by ATG12 up-regulation.
Ma J; Weng L; Jia Y; Liu B; Wu S; Xue L; Yin X; Mao A; Wang Z; Shang M
J Cell Mol Med; 2020 Mar; 24(5):2917-2930. PubMed ID: 31989778
[TBL] [Abstract][Full Text] [Related]
6. Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death.
Passacantilli I; Panzeri V; Terracciano F; Delle Fave G; Sette C; Capurso G
Oncol Rep; 2018 Apr; 39(4):1984-1990. PubMed ID: 29393478
[TBL] [Abstract][Full Text] [Related]
7. Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.
Kadera BE; Toste PA; Wu N; Li L; Nguyen AH; Dawson DW; Donahue TR
Clin Cancer Res; 2015 Jan; 21(1):157-65. PubMed ID: 25348515
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
Mikamori M; Yamada D; Eguchi H; Hasegawa S; Kishimoto T; Tomimaru Y; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y
Sci Rep; 2017 Feb; 7():42339. PubMed ID: 28198398
[TBL] [Abstract][Full Text] [Related]
9. Immunization with a multi-antigen targeted DNA vaccine eliminates chemoresistant pancreatic cancer by disrupting tumor-stromal cell crosstalk.
Qin H; Chen J; Bouchekioua-Bouzaghou K; Meng YM; Griera JB; Jiang X; Kong X; Wang M; Xu Q; Wong PP
J Transl Med; 2023 Oct; 21(1):702. PubMed ID: 37814317
[TBL] [Abstract][Full Text] [Related]
10. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
11. MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma.
Xiong G; Huang H; Feng M; Yang G; Zheng S; You L; Zheng L; Hu Y; Zhang T; Zhao Y
J Exp Clin Cancer Res; 2018 Apr; 37(1):76. PubMed ID: 29615098
[TBL] [Abstract][Full Text] [Related]
12. P21-activated kinase 1 (Pak1) signaling influences therapeutic outcome in pancreatic cancer.
Jagadeeshan S; Subramanian A; Tentu S; Beesetti S; Singhal M; Raghavan S; Surabhi RP; Mavuluri J; Bhoopalan H; Biswal J; Pitani RS; Chidambaram S; Sundaram S; Malathi R; Jeyaraman J; Nair AS; Venkatraman G; Rayala SK
Ann Oncol; 2016 Aug; 27(8):1546-56. PubMed ID: 27117533
[TBL] [Abstract][Full Text] [Related]
13. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
[TBL] [Abstract][Full Text] [Related]
14. C1GALT1 high expression is associated with poor survival of patients with pancreatic ductal adenocarcinoma and promotes cell invasiveness through integrin α
Kuo TC; Wu MH; Yang SH; Chen ST; Hsu TW; Jhuang JY; Liao YY; Tien YW; Huang MC
Oncogene; 2021 Feb; 40(7):1242-1254. PubMed ID: 33420364
[TBL] [Abstract][Full Text] [Related]
15. H2A.Z overexpression suppresses senescence and chemosensitivity in pancreatic ductal adenocarcinoma.
Ávila-López PA; Guerrero G; Nuñez-Martínez HN; Peralta-Alvarez CA; Hernández-Montes G; Álvarez-Hilario LG; Herrera-Goepfert R; Albores-Saavedra J; Villegas-Sepúlveda N; Cedillo-Barrón L; Montes-Gómez AE; Vargas M; Schnoor M; Recillas-Targa F; Hernández-Rivas R
Oncogene; 2021 Mar; 40(11):2065-2080. PubMed ID: 33627784
[TBL] [Abstract][Full Text] [Related]
16. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW
Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329
[TBL] [Abstract][Full Text] [Related]
17. Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance.
Gordon ER; Wright CA; James M; Cooper SJ
BMC Cancer; 2023 Jun; 23(1):524. PubMed ID: 37291514
[TBL] [Abstract][Full Text] [Related]
18. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
[TBL] [Abstract][Full Text] [Related]
19. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
[TBL] [Abstract][Full Text] [Related]
20. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.
Sumiyoshi H; Matsushita A; Nakamura Y; Matsuda Y; Ishiwata T; Naito Z; Uchida E
Oncol Rep; 2016 Jun; 35(6):3216-26. PubMed ID: 27035235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]